HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OPTH
Optimi Health Corp.
There isn't enough reported data to score OPTH yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OPTH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
OPTH's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OPTH PE Valuation
OPTH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OPTH Forward outlook
There aren't enough analyst estimates for OPTH to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
OPTH has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus OPTH down 205%.
OPTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$1.31 | +$1.32 |
| Q1 2023 | -$1.31 | +$1.61 |
| Q4 2022 | -$1.55 | +$1.18 |
| Q3 2022 | -$2.12 | +$0.02 |
OPTH is still losing money, but far less than before: $1.37 per share over the past year, against $2.92 at its worst in early 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OPTH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OPTH on profitability, with a higher operating margin.
OPTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $98.7K | -29% |
| Q1 2026 | $70K | +62% |
| Q2 2025 | $138.1K | +58% |
| Q1 2025 | $43.1K | -26% |
| Q4 2024 | $163.6K | +121% |
| Q3 2024 | $40.7K | +190% |
| Q2 2024 | $87.2K | +185% |
| Q1 2024 | $58.3K | +18% |
OPTH's revenue has slid since its 2024 peak: $98,700 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1523% | -1116 points |
| Q1 2026 | -1364% | +251 points |
| Q2 2025 | -406% | +445 points |
| Q1 2025 | -1615% | +11 points |
| Q4 2024 | -498% | +602 points |
| Q3 2024 | -2744% | +3779 points |
| Q2 2024 | -851% | +2101 points |
| Q1 2024 | -1626% | -1626 points |
OPTH's operating margin was −1523% last quarter, down 1025 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OPTH on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | -$1.4M |
| Q1 2026 | -$242.3K | -$188.7K |
| Q4 2025 | -$449.9K | -$217.4K |
| Q3 2025 | -$1M | -$462.4K |
| Q2 2025 | -$603.5K | +$137K |
| Q1 2025 | -$53.6K | +$472.8K |
| Q4 2024 | -$232.5K | +$1.1M |
| Q3 2024 | -$557.6K | +$363.3K |
OPTH has burned cash in almost every quarter: −$4M over the past year, against −$1M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OPTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OPTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +33% | +1.1M shares |
| 1 year | +33% | +1.1M shares |
| 3 years | +84% | +2M shares |
OPTH has 4M diluted shares, up 33% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OPTH hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OPTH Net Leverage
OPTH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OPTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.5 | Oversold |
| Stochastic | 11.4 | Oversold |
OPTH's weekly RSI is 27 (oversold) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OPTH PE vs Healthcare Sector
OPTH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
OPTH has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus OPTH above 0 of 4.
OPTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 35% below |
| 20 week MA | $4.24 | 49% below |
| 50 week MA | $5.63 | 61% below |
| 100 week MA | $5.22 | 58% below |
OPTH is in a downtrend: it's below all four of its weekly moving averages, and 58% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over OPTH on returns for 2026, with the stronger performance.
OPTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $7.20 | $4.70 | -35% |
| 2025 | $4.70 | $7.26 | +54% |
| 2026 YTD | $7.26 | $2.18 | -70% |
OPTH has finished lower in one of the last two years. It's down 70% so far in 2026.